SURMOUNT-3 deep dive: tirzepatide after intensive lifestyle intervention
Last verified 2026-05-28 · 3 · Completed; primary results reported (Wadden 2023, Nat Med) · NCT04657016 ↗
SURMOUNT-3 (NCT04657016) is the phase-3 trial that tested whether tirzepatide adds meaningful weight loss on top of a successful lifestyle program — the clinical scenario that drives most prior-authorization fights between patients and insurers. Eli Lilly enrolled 806 adults with body-mass index of at least 30 kg/m², or at least 27 kg/m² with a weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) and without diabetes, into a 12-week intensive lifestyle intervention featuring a low-calorie diet, at least 150 minutes per week of physical activity, and weekly counseling sessions. Only the 579 participants who lost at least 5% of their body weight during the lead-in were randomized 1:1 to weekly subcutaneous tirzepatide (titrated to a maximum tolerated dose of 10 mg or 15 mg) or matching placebo for 72 additional weeks, with the lifestyle program continuing throughout. Results published by Wadden and colleagues in Nature Medicine on October 15, 2023 (PMID 37840095) showed a mean additional weight change of -18.4% on tirzepatide versus +2.5% on placebo from the randomization point.
- Enrollment
- 579
- Duration
- 12-week intensive lifestyle lead-in plus 72 weeks of randomized treatment (total 84 weeks); adverse-event surveillance through week 76
- Drug
- Tirzepatide
- Population
- Adults aged 18 or older with body-mass index of at least 30 kg/m², or at least 27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). Type 2 diabetes was an exclusion, as were pancreatitis history, medullary thyroid carcinoma or MEN-2 family history, active major depressive disorder within 2 years, and any lifetime suicide attempt. Of the 806 who started the 12-week lead-in lifestyle program, 579 (72%) achieved the protocol-required at-least-5% weight reduction and were randomized. At randomization, mean body weight was 101.87 kg, 63% were female (364/579), 86% were white (498/579), and the mean age was 45.6 years.
Primary endpoint
Additional mean percent change in body weight from randomization to week 72 (coprimary, treatment-regimen estimand, ITT)
Treatment arm
-18.4% (SE 0.7)
Comparator
+2.5% (SE 1.0)
Treatment difference: Estimated treatment difference -20.8 percentage points (95% CI -23.2 to -18.5; P<0.001)
Per the ClinicalTrials.gov results posting using the same MMRM model, the corresponding LS-mean estimates were -21.1% on tirzepatide vs +3.3% on placebo (similar magnitudes, slightly different denominators between publication and registry). Together with the ~7% mean weight loss already achieved during the 12-week lead-in, this represents total weight loss approaching the mid-twenties on tirzepatide vs roughly a 3-4% net loss on placebo.
Secondary endpoints
| Endpoint | Treatment | Comparator | Difference |
|---|---|---|---|
| Coprimary: proportion achieving ≥5% additional body-weight reduction at week 72 (from randomization) Nearly nine of ten tirzepatide participants kept losing weight after the lead-in, while roughly one in six placebo participants did. | 87.5% (SE 2.2) | 16.5% (SE 3.0) | Odds ratio 34.6 (95% CI 19.2 to 62.6; P<0.001) |
| Proportion maintaining ≥80% of the weight lost during the 12-week lifestyle lead-in at week 72 Direct test of the durability question. Without drug, only about a third of participants held on to most of their lifestyle-phase loss; with tirzepatide, almost everyone did. | 98.6% | 37.8% | Logistic regression favored tirzepatide; P<0.001 |
| Proportion achieving ≥10% additional body-weight reduction from randomization to week 72 | 88.0% | 4.8% | P<0.001 |
| Proportion achieving ≥15% additional body-weight reduction from randomization to week 72 | 73.9% | 2.1% | P<0.001 |
| Proportion achieving ≥20% additional body-weight reduction from randomization to week 72 More than half of tirzepatide participants lost an additional ≥20% on top of what they had already lost during the lifestyle lead-in. | 54.9% | 1.0% | P<0.001 |
| Change in waist circumference from randomization to week 72 (cm) | -16.8 cm (SE 0.56) | +1.1 cm (SE 0.58) | Estimated treatment difference roughly -17.9 cm |
| Change in systolic blood pressure from randomization to week 72 (mmHg) Placebo participants' systolic blood pressure rose alongside their weight regain, widening the between-group gap. | -5.8 mmHg (SE 0.73) | +4.4 mmHg (SE 0.76) | Estimated treatment difference roughly -10.2 mmHg |
| Percent change in triglycerides from randomization to week 72 | -25.8% (SE 1.61) | +3.0% (SE 2.34) | Estimated treatment difference roughly -29 percentage points |
| Percent change in total cholesterol from randomization to week 72 | -3.0% (SE 0.97) | +5.2% (SE 1.11) | Estimated treatment difference roughly -8 percentage points |
| Change in HbA1c from randomization to week 72 (%) Participants were non-diabetic at entry; the HbA1c drop reflects shifts within the normoglycemic/prediabetic range. | -0.46% (SE 0.020) | +0.01% (SE 0.022) | Estimated treatment difference roughly -0.47 percentage points |
| Change in fasting plasma glucose from randomization to week 72 (mg/dL) | -8.8 mg/dL (SE 0.82) | +2.4 mg/dL (SE 0.86) | Estimated treatment difference roughly -11.2 mg/dL |
Adverse events
| Event | Treatment rate | Comparator rate |
|---|---|---|
| Nausea Most common AE on tirzepatide; typically mild-to-moderate and concentrated during the 20-week dose-escalation phase. | 39.7% (114/287) | 14.0% (41/292) |
| Diarrhea | 31.0% (89/287) | 9.2% (27/292) |
| Constipation | 23.0% (66/287) | 6.8% (20/292) |
| Vomiting Largest relative excess of any GI event vs placebo. | 18.1% (52/287) | 1.4% (4/292) |
| Injection-site reaction | 11.1% (32/287) | 1.0% (3/292) |
| Abdominal pain | 10.5% (30/287) | 2.4% (7/292) |
| Dyspepsia | 9.4% (27/287) | 3.1% (9/292) |
| Decreased appetite | 9.4% (27/287) | 4.1% (12/292) |
| Headache | 9.4% (27/287) | 7.5% (22/292) |
| Alopecia (hair loss) Hair loss tends to track the magnitude of weight loss rather than the drug itself; rates were similarly elevated in SURMOUNT-1. | 7.0% (20/287) | 1.4% (4/292) |
| Serious adverse events (any) No single SAE term affected more than two tirzepatide participants. One death occurred in each arm; neither was assessed as related to study drug. | 5.9% (17/287) | 4.8% (14/292) |
Clinical significance
SURMOUNT-3 directly answers the question payers and prior-authorization reviewers most often ask: is tirzepatide really additive to lifestyle change, or are people on the drug simply skipping the work? The trial design — a 12-week intensive lifestyle program first, then randomization only among those who already lost at least 5% — controls for the motivation and capability that confound naive comparisons. From a starting point where every participant had already done the lifestyle work, tirzepatide added another 18.4% mean weight loss over 72 weeks, while placebo participants regained 2.5% despite continuing the same counseling and food/activity prescription. The 98.6% maintenance rate (versus 37.8% on placebo) is the strongest evidence to date that for most people, lifestyle alone does not sustain weight loss without pharmacotherapy — and that adding tirzepatide does not waste the lifestyle effort, it compounds it. SURMOUNT-3 mirrors STEP-3 (semaglutide plus intensive behavioral therapy) and is now routinely cited in coverage-policy arguments for prior authorizations that require a documented lifestyle trial.
Frequently asked questions
Does tirzepatide work without intensive lifestyle intervention?
SURMOUNT-1 already showed it does — that trial enrolled adults with obesity, paired tirzepatide with standard monthly lifestyle counseling rather than the structured program used in SURMOUNT-3, and reported mean weight loss of 20.9% at 15 mg over 72 weeks. SURMOUNT-3 is the complementary trial that tests whether tirzepatide adds value on top of an intensive lifestyle program. The short answer from both trials together: tirzepatide produces large weight loss whether or not it is paired with intensive behavioral support, but the absolute magnitudes are similar across designs (around 20% from baseline), suggesting the drug is the dominant driver of weight change in both settings. Lifestyle programs help with sustainability, food quality, exercise capacity, and metabolic markers, and clinical guidelines still recommend behavioral support alongside any obesity medication.
What counted as intensive lifestyle intervention in SURMOUNT-3?
Participants worked with trained interventionists on a low-calorie diet (initially around 1,200 to 1,500 kcal per day depending on starting weight, designed to produce a 500-kcal-per-day deficit), at least 150 minutes per week of moderate-intensity physical activity ramping toward 300 minutes per week, and weekly individual or group counseling sessions during the 12-week lead-in. The behavioral curriculum drew on the same Diabetes Prevention Program and Look AHEAD methodology used in earlier obesity trials. After randomization, the lifestyle support continued throughout the 72-week treatment phase, with sessions transitioning to lower frequency over time. The intensity is roughly comparable to STEP-3's intensive behavioral therapy arm; both designs ensured that any drug effect was layered on top of an active lifestyle intervention rather than substituting for it.
How does SURMOUNT-3 compare to STEP-3?
STEP-3 paired semaglutide 2.4 mg with intensive behavioral therapy from week zero and reported mean weight loss of 16.0% at week 68. SURMOUNT-3 ran the lifestyle phase first, then randomized only the responders to tirzepatide or placebo for 72 more weeks, and reported an additional 18.4% on tirzepatide from the randomization point — meaning total weight loss across the full 84 weeks reached roughly 26% on tirzepatide and roughly 3-4% net on placebo. The trials are not head-to-head and the populations differ slightly (SURMOUNT-3 selected for lifestyle responders, STEP-3 did not). The direct head-to-head comparison between tirzepatide and semaglutide for weight loss was answered later by SURMOUNT-5 (Aronne 2025).
Did the 12-week lifestyle run-in skew the results?
The run-in does shape interpretation, but in a way that strengthens rather than weakens the case for tirzepatide. Because randomization only included participants who had already lost at least 5% with lifestyle alone, the population was self-selected for behavioral capability and adherence. That selection should bias the placebo arm toward better outcomes, not worse — these were the people most likely to keep losing weight without medication. Despite that, placebo participants regained 2.5% on average and only 37.8% maintained at least 80% of their initial loss, while 98.6% of tirzepatide participants did. The run-in design also answers a different question than SURMOUNT-1: whether the drug adds anything for people who already proved they can lose weight on lifestyle. The answer, in this trial, was yes — substantially.
Should insurance require intensive lifestyle intervention before approving Zepbound?
Many commercial and Medicaid plans currently require documentation of a supervised lifestyle program (often 3 to 6 months) before approving GLP-1 medications for obesity. SURMOUNT-3 is the trial most commonly cited in appeals and policy discussions on both sides of this question. Proponents of the requirement point to the trial as evidence that lifestyle can produce 5% or more weight loss for many people on its own. Critics point to the same trial as evidence that lifestyle-only losses are not sustained — under the 37.8% maintenance rate in the placebo arm, the requirement essentially asks patients to lose weight, regain most of it, and then qualify for the medication that would have helped them keep the loss. Current AACE and Obesity Society guidelines support adding pharmacotherapy when lifestyle alone is insufficient; SURMOUNT-3 quantified what 'insufficient' looks like at the 12-month mark.
How tolerable was tirzepatide in SURMOUNT-3 compared to other trials?
Gastrointestinal adverse events were the dominant tolerability issue and tracked the pattern seen in SURMOUNT-1 and SURMOUNT-2. Nausea (39.7% vs 14.0%), diarrhea (31.0% vs 9.2%), constipation (23.0% vs 6.8%), and vomiting (18.1% vs 1.4%) all ran several-fold higher on tirzepatide than placebo and concentrated during the 20-week dose-escalation phase. Most events were mild to moderate. Serious adverse events were similar between groups (5.9% on tirzepatide vs 4.8% on placebo), with no single SAE term affecting more than two participants in either arm. Hair loss (alopecia) was reported in 7.0% on tirzepatide versus 1.4% on placebo, consistent with the pattern of elevated hair-loss reporting that tracks the magnitude of weight loss across obesity trials rather than the drug class itself.
References
- 1.Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, Halpern B, Zhang S, Chen J, Bunck MC, Ahmad NN, Forrester T. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023. PMID: 37840095.
- 2.U.S. National Library of Medicine. A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (SURMOUNT-3) — Study Results. ClinicalTrials.gov, NCT04657016. 2024. https://clinicaltrials.gov/study/NCT04657016
- 3.Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185.
- 4.Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021. PMID: 33625476.
- 5.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.